The University Of Kentucky Research Foundation (the Research Foundation) was awarded a $640,068 Project Grant from the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866) to conduct the "IMPACTING INFLAMMATION THROUGH MECHANISTIC TARGET OF RAPAMYCIN (IMTOR)" study. This ancillary study to the NIA-funded EVERLAST trial (U01AG076941) will quantify the impact of the rapamycin analog everolimus on chronic inflammation in immune cells, a key driver of age-related health declines. The IMTOR study will focus primarily on CD4+ T cells as dominant sources of inflammation, while also analyzing myeloid cells. It aims to determine if everolimus can reduce inflammation through improved bioenergetics and redox balance in immune cells, and how these changes relate to the hallmarks of aging outcomes measured in the EVERLAST parent trial. The award period is from September 1, 2024 to May 31, 2028.
Generated 1/28/25, 10:10 AM